ClinicalTrials.gg

Program

KT502

A development code.

Its studies are mostly in Arthritis, Rheumatoid, led by Kali Therapeutics.

Furthest: phase 1, since Apr 27, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kali Therapeutics11 open or runningphase 1since Apr 27, 2026Apr 27, 2026Dec 2027phase 1 · NCT07564154

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2026First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07564154 · 27 planned · Australia, New Zealand

Ahead

  1. Dec 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07564154

TargetBeta

CD19 →CD3E →read by rule
“KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501ruleKali Therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07564154Arthritis, Rheumatoid · Australia, New Zealand1RecruitingDec 202727

How it is read

Names in the registry

  • “KT502”, 1 entry

Codes read as this program: KT502.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.